ArticleAdvanced healthcare materials2026
Biphasic Co-Delivery of Curcumin and 5-FU using 3D-Printed Dissolving Microneedles for Skin Cancer Therapy.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dissolving microneedle (MN) arrays are a minimally invasive strategy for localized transdermal chemotherapy; however, their translation is limited by drug loading, reproducible dosing, and the difficulty of incorporating chemically distinct drugs into printable matrices. Although MN-mediated delivery of curcumin and 5-fluorouracil (5-FU) has previously been reported using inkjet/coating-based approaches, those systems deposit drug formulations onto preformed solid MNs and are therefore constrained by surface coating uniformity, limited matrix integration, possible drug loss during handling, and less direct control over geometry-dependent dose. Here, we report a distinct one-step DLP 3D-printing strategy in which hydrophilic 5-FU and hydrophobic curcumin are incorporated directly into a single PEGDA/VP photocurable resin before fabrication. The optimized resin enabled high-resolution MN arrays with CAD-defined dimensions, sharp tips, insertion efficiency above 95%, high drug entrapment, and controlled/biphasic release behavior. Importantly, the work demonstrates that curcumin's optical absorbance can be managed through exposure optimization without compromising print fidelity, allowing dual-drug-loaded dissolving MNs to be manufactured directly from the therapeutic resin. These findings establish the system as a formulation-process-performance platform rather than a first report of curcumin/5-FU MN co-delivery, providing a scalable and customizable approach for localized skin-cancer drug delivery that warrants future biological validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.